IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

$BACK
Medical Specialities
Health Care
Get the next $BACK alert in real time by email
false --12-31 0001729944 0001729944 2025-03-25 2025-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2025

 

IMAC Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38797   83-0784691

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

3401 Mallory Lane, Suite 100

Franklin, Tennessee

  37067
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (844) 266-4622

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BACK   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01. Entry into a Definitive Material Agreement.

 

Waiver and Amendment to Common Stock Purchase Agreement

 

On March 25, 2025, IMAC Holdings, Inc. (the “Company”) and Keystone Capital Partners, LLC (“Keystone”) entered into a Waiver and Amendment (the “Waiver and Amendment”) to the Common Stock Purchase Agreement, dated November 12, 2024, by and between the Company and Keystone (the “ELOC”). Pursuant to the Waiver and Amendment, Keystone waived certain requirements of the ELOC for the issuance and sale by the Company of shares of its common stock, par value $0.001 per share (the “Common Stock”), including the Closing Sale Price of at least $0.25, and certain restrictions stemming from rules of The Nasdaq Stock Market. In addition, the definition of Eligible Market was amended to include the OTCQX Market, the OTCQB Market and the OTC Pink Market.

 

The foregoing description of the Waiver and Amendment is not complete and is qualified in its entirety by reference to the full text of the Waiver and Amendment, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.

 

Amendments to Promissory Notes

 

On March 25, 2025, the Company entered into amendments (the “Amendments”) to each of the promissory notes issued by the Company to certain lenders on February 14, 2025, February 27, 2025, March 6, 2025 and March 13, 2025, in the aggregate principal amount of $349,500 (the “February-March Promissory Notes” and, collectively with the February 14 Promissory Notes, the “Notes”) The Amendments (i) increase the principal amount of promissory notes issued by the Company with which the Notes rank pari passu to reflect the issuance of the March 25 Promissory Notes (as defined below) and to (ii) increase the amount of additional promissory notes that are authorized to be issued pari passu with the Notes to $649,500.

 

The foregoing description of the Amendments is not complete and is qualified in its entirety by reference to the full text of the Form of Amendment to Promissory Note, a copy of which is filed herewith as Exhibit 4.1 and is incorporated herein by reference.

 

The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

Additional Promissory Notes

 

On March 25, 2025, the Company issued promissory notes (the “March 25 Promissory Notes”) to certain lenders (the “Lenders”) in the aggregate principal amount of $84,000, for an aggregate purchase price from the Lenders of $60,000.

 

The March 25 Promissory Notes are unsecured and mature on December 24, 2025. The Company may prepay any portion of the outstanding principal at any time without penalty.

 

 
 

 

The March 25 Promissory Notes include customary representations, warranties and covenants and sets forth certain events of default after which the outstanding principal may be declared immediately due and payable, including certain types of bankruptcy or insolvency events of default involving the Company.

 

The foregoing description of the March 25 Promissory Notes is not complete and is qualified in its entirety by reference to the full text of the Form of March 25 Promissory Notes, a copy of which is filed herewith as Exhibit 4.2 and is incorporated herein by reference.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

The information included in Item 5.07 of this Current Report on Form 8-K is incorporated by reference in this Item 5.03 to the extent required herein.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On March 26, 2025, Company held a special meeting of its stockholders (the “Special Meeting”) virtually, at 11:00 a.m., Central time. As of January 27, 2025, the record date of the Special Meeting, there were a total of 2,071,812 shares of the Company’s common stock issued and outstanding and entitled to vote at the Special Meeting. A total of 1,151,180 votes were represented at the Special Meeting, and a quorum was present. The following proposals were approved by the stockholders:

 

1. the potential issuance of an excess of 19.99% of the Company’s outstanding common stock under the Company’s Series G Preferred Stock and related warrants (the “Series G Issuance Proposal”);

 

2. the potential issuance of an excess of 19.99% of our outstanding common stock pursuant to the Committed Equity Financing (as defined in the Proxy Statement) (the “Committed Equity Financing Issuance Proposal”);

 

3. an amendment to the Company’s Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance (the “Authorized Common Stock Increase Proposal”); and

 

4. an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s Common Stock, subject to the Board of Directors’ discretion (the “Reverse Stock Split Proposal”).

 

For more information about the foregoing proposals, please see the Company’s Definitive Proxy Statement filed on February 11, 2025 and supplemented from time to time thereafter (the “Proxy Statement”).

 

The number of votes cast for, against, and where applicable, votes withheld, as well as abstentions and whether each proposal was approved, is set forth below.

 

1. The Series G Issuance Proposal.

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTE
336,569   157,860   3,257   653,494

 

Accordingly, the Series G Issuance Proposal was approved.

 

2. The Committed Equity Financing Issuance Proposal.

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTE
336,550   157,875   3,261   653,494

 

Accordingly, the Committed Equity Financing Issuance Proposal was approved.

 

 

 

 

3. The Authorized Common Stock Increase Proposal.

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTE
915,273   229,308   6,599   0

 

Accordingly, the Authorized Common Stock Increase Proposal was approved.

 

4. The Reverse Stock Split Proposal.

 

FOR   AGAINST   ABSTAIN   BROKER NON-VOTE
906,181   238,761   6,238   0

 

Accordingly, the Reverse Stock Split Proposal was approved.

 

Effective upon the approval of the Authorized Common Stock Increase Proposal, on March 26, 2025 the Company formally completed the increase of the authorized Common Stock from 60,000,000 shares to 120,000,000 shares by filing a Certificate of Amendment with the Delaware Secretary of State, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

 

Item 8.01

Other Events.

 

On March 19, 2025, the Company issued a promissory note (the “March 19 Promissory Note”) to Jeffrey Busch in the aggregate principal amount of $16,500, for an aggregate purchase price from Mr. Busch of $15,000. The March 19 Promissory Note is unsecured and matures on the earlier of (i) the date of consummation of any offering or offerings, individually or in the aggregate, of securities with gross proceeds of at least $1,000,000, and (ii) November 14, 2025. The Company may prepay any portion of the outstanding principal at any time without penalty.

 

The March 19 Promissory Note includes customary representations, warranties and covenants and sets forth certain events of default after which the outstanding principal may be declared immediately due and payable, including certain types of bankruptcy or insolvency events of default involving the Company.

 

The foregoing description of the March 19 Promissory Note is not complete and is qualified in its entirety by reference to the full text of the March 19 Promissory Note, a copy of the form of which is filed as Exhibit 4.3 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

Exhibit No.   Description
3.1   Amendment to the Certificate of Incorporation of the Company.
4.1   Form of Amendment to Promissory Note, dated March 25, 2025.
4.2   Form of Promissory Note dated March 25, 2025.
4.3   Form of Promissory Note dated March 19, 2025.
10.1   Waiver and Amendment Dated March 25, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 27, 2025

 

  IMAC HOLDINGS, INC.
     
  By: /s/ Faith Zaslavsky
  Name: Faith Zaslavsky
  Title: Chief Executive Officer

 

 

Get the next $BACK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BACK

DatePrice TargetRatingAnalyst
More analyst ratings

$BACK
Press Releases

Fastest customizable press release news feed in the world

See more
  • Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

    Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

    $BACK
    Medical Specialities
    Health Care
  • Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

    Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is addressed by the Palmetto GBA MolDx "Proteomics Testing" article (A59636). This milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into Ignite Proteomics. PLA codes like 0249U are essential building blocks for new diagnostics, as

    $BACK
    Medical Specialities
    Health Care
  • Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

    The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), announces the publication of a significant study in the British Journal of Cancer titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". This research underscores the critical importance of measuring functional protein activation within the AKT–mTOR signaling pathway to accurately predict patient responses to targeted cancer therapies. Advancing Precision Oncology Through Direct Protein Activation Measu

    $BACK
    Medical Specialities
    Health Care

$BACK
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BACK
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BACK
SEC Filings

See more

$BACK
Leadership Updates

Live Leadership Updates

See more
  • IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

    Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono

    $BACK
    Medical Specialities
    Health Care
  • DayDayCook Names Jeffrey Ervin as Co-Chief Financial Officer

    NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o

    $BACK
    $DDC
    Medical Specialities
    Health Care
    Packaged Foods
    Consumer Staples
  • IMAC Holdings Announces Leadership Succession

    Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami

    $BACK
    Medical Specialities
    Health Care

$BACK
Financials

Live finance-specific insights

See more
  • IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

    FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,

    $BACK
    Medical Specialities
    Health Care
  • IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

    Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) ("Theralink"), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per s

    $BACK
    Medical Specialities
    Health Care
  • IMAC Holdings, Inc announces the sale of The BackSpace

    BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations. "We are excited for the Curis team to support and grow the business going forward while we return our focus to non-surgical medical care for a person's optimal orthopedic function, stability, and mobility," said Jeff Ervin, Chief Executive Officer of IMAC. In addition to the sale of The BackSpace, the Company's Chief Operating Officer, Dr. Ben Lerner, ann

    $BACK
    Medical Specialities
    Health Care

$BACK
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more